EMEA-002880-PIP01-20

Table of contents

Key facts

Active substance
COVID-19 vaccine (Ad26.COV2-S (recombinant))
Therapeutic area
Infectious diseases
Decision number
P/0059/2021
PIP number
EMEA-002880-PIP01-20
Pharmaceutical form(s)
Suspension for injection in cartridge
Condition(s) / indication(s)
Prevention of Coronavirus disease 2019 (COVID-19)
Route(s) of administration
Intramuscular use
Contact for public enquiries
Janssen-Cilag International N.V.

Tel. +32 14602111
E-mail: contact@Janssen-emea.com

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating
Average
1 rating